IsoPlexis launches new COVID-19 proteomics grant challenge

By The Science Advisory Board staff writers

August 26, 2020 -- IsoPlexis has unveiled its Single-Cell Proteomics COVID-19 Grant Challenge, which will award 12 of the company's IsoCode or CodePlex chips to two winners for proposed projects that demonstrate research novelty and innovation using single-cell proteomics.

Via the grant challenge, researchers will be able to use the company's single-cell proteomics technology to help resolve the underlying functional mechanisms of COVID-19, thus aiding in accelerating the development of therapies and vaccines, IsoPlexis said. Researchers can find out more information about the challenge and submit an abstract on the firm's website.

Submissions must be received by September 30 and the experiments must be completed by November 30.

IsoPlexis, Lonza partner on cell therapy manufacturing
IsoPlexis and Lonza have partnered to advance automated cell therapy manufacturing.
IsoPlexis partners with Columbia for vaccine development
IsoPlexis is partnering with Columbia University's Division of Infectious Diseases to create a vaccine for COVID-19. IsoPlexis' Single-Cell Secretome...

Copyright © 2020

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter